Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Case Rep Med. 2010;2010:657579. doi: 10.1155/2010/657579. Epub 2010 Mar 21.

Response to hydralazine-valproate in a patient with mycosis fungoides.

Author information

  • 1Unidad de Investigación Biomédica en Cancer, Instituto de Investigaciones Biomédicas, Instituto Nacional de Cancerología, UNAM, San Fernando 22, Tlalpan 14080, Mexico City, Mexico.

Abstract

Histone deacetylase (HDAC) inhibitors have shown significant activity in the treatment of cutaneous T-cell lymphomas (CTCL). The epigenetic alterations of CTCL not only are limited to altered histone acetylation but also include aberrant DNA gene methylation hence, the combination of an HDAC inhibitor with a DNA demethylating agent is a promising therapy to be tested. Here we report a mycosis fungoides patient having a dramatic response to hydralazine and valproate, two repositioned drugs as HDAC and DNA methylation inhibitors, respectively.

PMID:
20339522
[PubMed]
PMCID:
PMC2842973
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk